Skip to main content
Premium Trial:

Request an Annual Quote

Hybrigenics Gets $510M to Screen Protein Interaction Inhibitors

NEW YORK (GenomeWeb News) – Hybrigenics has received €400,000 ($510.4 million) to screen inhibitors of protein interaction under a collaboration with the Masterswitch European union research project.

Hybrigenics will use its protein interaction technologies and expertise in the field of chronic inflammatory diseases, the Paris-based firm said today. It will develop a high-throughput assay and screen its library of 100,000 compounds and its collection of around 2,000 natural substances. The goal is to identify small-molecule inhibitors of a therapeutically relevant protein interaction, said Hybrigenics.

The firm will receive the funding over the first two years of a five-year collaboration.

The Masterswitch project is part of the EU's 7th Framework Programme and includes a consortia of 16 participants. The primary objective of the project is to develop new treatments for chronic inflammatory diseases.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.